Angle CEO Andrew Newland says he is absolutely overjoyed with the FDA clearance received today for its Parsortix cancer cell harvesting technology.
Newland said it has taken over six years of 'sustained work' to get this clearance, which is the first
ever for a system to harvest cancer cells for subsequent analysis.
"It will open a whole new approach for treating cancer patients," suggests Newland.
"Parsortix can become the de facto standard for recovering cells for cancer management."